Multi Omics Molecular Characteristics and Immunophenotyping of Lung Signet Ring Cell Carcinoma

NCT07207278 · clinicaltrials.gov ↗

RECRUITING

Status

39

Enrollment

OTHER

Sponsor class

Conditions

Signet Ring Cell Carcinoma of the Lung

Interventions

DRUG: Patients with specific TIME subtype and ALK fusion mutations (confirmed via RNA-seq and OncoKB annotation) will receive tyrosine kinase inhibitors (TKIs, e.g., alectinib or crizotinib) as first-line

Sponsor

First People's Hospital of Hangzhou

Collaborators

[object Object]
[object Object]